Du Tonghua, Shi Ying, Xu Shengnan, Wan Xiaoyu, Sun Haiyin, Liu Bin
Department of Breast Surgery, The Second Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
Onco Targets Ther. 2020 Jul 21;13:7075-7087. doi: 10.2147/OTT.S255226. eCollection 2020.
Breast cancer (BC) is the most common cancer and the leading cause of death in women. Advances in early diagnosis and therapeutic strategies have decreased the mortality of BC and improved the prognosis of patients to some extent. However, the development of drug resistance has limited the success rate of systemic therapies. Long non-coding RNAs (lncRNAs) are involved in drug resistance in BC via various mechanisms, which contribute to a complex regulatory network. In this review, we summarize the latest findings on the mechanisms underlying drug resistance modulated by lncRNAs in BC. In addition, we discuss the potential clinical applications of lncRNAs as targeted molecular therapy against drug resistance in BC.
乳腺癌（BC）是女性中最常见的癌症，也是主要的死亡原因。早期诊断和治疗策略的进步降低了乳腺癌的死亡率，并在一定程度上改善了患者的预后。然而，耐药性的发展限制了全身治疗的成功率。长链非编码RNA（lncRNAs）通过多种机制参与乳腺癌的耐药性，这构成了一个复杂的调控网络。在本综述中，我们总结了lncRNAs调控乳腺癌耐药性机制的最新研究成果。此外，我们还讨论了lncRNAs作为针对乳腺癌耐药性的靶向分子疗法的潜在临床应用。
